Abstract

Manifestations of mantle cell lymphoma were recognized in the 1970s as distinct from those associated with the more readily classifiable lymphomas. It was not until the 1990s, however, that observation of a combination of immunologic, cytogenetic, and molecular genetic abnormalities characteristic of this new malignancy confirmed its existence. The clinical and pathologic entity was named mantle cell lymphoma and in 1994 was incorporated into the Revised European American Lymphoma Classification. Mantle cell lymphoma is a CDS positive, B-cell lymphoma that usually displays the t(11;14). The lymphoma has a striking male predominance and is widely disseminated at diagnosis in 80% of patients. Mantle cell lymphoma responds poorly to available therapies, and the median survival is approximately 3 years.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalONCOLOGY
Volume12
Issue number10 SUPPL. 8
StatePublished - Dec 1 1998

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this